Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis-Reference-Cited by-同舟云学术

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

Published:2017-02 Issue: Volume:16 Page:41-50
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Baker David,Marta Monica,Pryce Gareth,Giovannoni Gavin,Schmierer Klaus

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference100 articles.

1. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - targeting T or B cells?;Agahozo;Mult. Scler. Relat. Disord.,2016

2. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Ann. Neurol.,2016

3. Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study;Aquis;Mult. Scler. J.,2015

4. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis;Arnold;BMC Neurol.,2014

5. EBV and autoimmunity;Ascherio;Curr. Top. Microbiol. Immunol.,2015

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Setting;Clinical Neuropharmacology;2024-09-12

2. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease;Current Neurology and Neuroscience Reports;2024-09-11

3. Single-cell transcriptome sequencing reveals altered peripheral blood immune cells in patients with severe tuberculosis;European Journal of Medical Research;2024-08-29

4. Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?;Multiple Sclerosis and Related Disorders;2024-07

5. European flow cytometry quality assurance guidelines for the diagnosis of primary immune deficiencies and assessment of immune reconstitution following B cell depletion therapies and transplantation;Cytometry Part B: Clinical Cytometry;2024-06-28